About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
- 2014 Rate Card & Production Specs
- 2013 Rate Card & Production Specs
- Advertising Due Dates
- BPA Statement
Statement of Purpose
Guidelines for Authors
The Need to Reduce the Federal Deficit Puts Seniors and Providers on Notice
In view of changing Medicare payment policies, hospitals reassess pharmacy procedures.
Investigational Combinations for the Treatment of BRAF-Mutated Metastatic Melanoma
The arrival of ipilimumab and vemurafenib has provided oncologists with new choices in a field in which options were slim and the prognosis was grim. Combination therapy may lead to an improved survival benefit.
Cardiometabolic Consequences of Therapy for Chronic Schizophrenia Using Second-Generation Antipsychotic Agents in a Medicaid Population
Clinical and Economic Evaluation
A health economic model was constructed to predict the 5-year incidence of coronary heart disease and diabetes and associated costs after treatment in patients using second-generation antipsychotic agents.
Alex Ward, PhD, MRPharmS; Peter Quon, MPH; Safiya Abouzaid, PharmD; Noah Haber, MA; Saeed Ahmed, MD; and Edward Kim, MD, MBA
Drug therapies for multiple myeloma, mantle-cell lymphoma, and myelodysplastic syndromes
Generic biologics (e.g., biosimilars) and medication safety related to Joint
Commission hospital accreditation standards
Michele B. Kaufman, PharmD, RPh
The Result: Drug Orders Are Omitted
Drug orders can be accidentally omitted or misread if a scanner pulls too many pages through at once.
Matthew Grissinger, RPh, FASCP
Technical Complexities of Labels Could Compromise Utility
A proposed FDA rule on unique device identifcation could complicate billing and bar-coding procedures for hospitals.
FDA approvals, drug indications, and updates
Cabozantinib (Cometriq) for metastatic medullary thyroid cancer; ponatinib (Iclusig) for two forms of leukemia; and raxibacumab for inhalational anthrax
Marvin M. Goldenberg, PhD, RPh, MS
Farah Khorassani, PharmD, BCPS; and Olga Hilas, PharmD, MPH, BCPS, CGP